Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Anantharaman Vathsala(National University of Singapore), Robert D. Toto(Southwestern Medical Center), George L. Bakris(Pennsylvania State System of Higher Education), Alfredo E. Farjat(Bayer (United Kingdom)), Trine Finnes, Gerasimos Filippatos(National and Kapodistrian University of Athens), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), László Rosivall(Semmelweis University), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki), Sanjay Kaul(Memorial Hermann), Christoph Wanner(Universitätsklinikum Würzburg), Richard J. MacIsaac, Sheldon W. Tobe(Sunnybrook Health Science Centre), Katja Rohwedder(Bayer (Germany)), Martin Prázný, Magdalena Madero Rovalo, Luís M. Ruilope(Bayer (Germany)), Bertram Pitt(Bayer (Germany)), Theodora Temelkova‐Kurktschiev, Ellen Burgess, Adriaan Kooy, Guntram Schernthaner(Rudolfinerhaus Hospital), Roland E. Schmieder(Universitätsklinikum Erlangen), Wanzhu Tu(Indiana University Health), Robert Lawatscheck(Bayer (Germany)), Janusz Gumprecht(Medical University of Silesia), Joseph A. Eustace(Johns Hopkins University), Daisuke Koya(Kanazawa Medical University), Pieter Gillard(Research Foundation - Flanders), Jorma Strand, Takashi Wada(FIND), Carlos Jaramillo, Peter Rossing(Steno Diabetes Centers), Juliana C.N. Chan(Chinese University of Hong Kong), Maria Eugênia Fernandes Canziani, Youssef M.K. Farag(Bayer (United States)), Fernando Teixeira e Costa, Andrés Ángelo Cadena Bonfanti, Froilan DeLeon, Stefan D. Anker(Bayer (Germany)), Augusto Vallejos, Ron T. Gansevoort(University Medical Center Groningen)
Annals of Internal Medicine
December 1, 2023
Cited by 94


Related Papers